The global market for fine chemical intermediates is vast, and for researchers and manufacturers requiring specific compounds like 6,7-Dimethoxy-3,4-dihydroquinazolin-4-one (CAS: 13794-72-4), finding reliable suppliers is a strategic necessity. This quinazoline derivative is highly sought after for its role in pharmaceutical synthesis, particularly as an intermediate for Gefitinib.

When initiating a search to buy 6,7-Dimethoxy-3,4-dihydroquinazolin-4-one, it's important to consider suppliers who not only offer competitive pricing but also guarantee high purity (e.g., >98% HPLC) and consistent quality. Manufacturers based in China have become significant players in this market, offering a combination of production scale and cost-effectiveness.

Key attributes to look for in a supplier include:

  • Manufacturing Capability: The ability to produce the compound in the required quantities, whether for R&D or commercial scale.
  • Quality Assurance: Strong internal quality control processes and readily available documentation like Certificates of Analysis (COA) and Safety Data Sheets (SDS).
  • Product Information: Clear listing of specifications, including CAS number (13794-72-4) and purity metrics.
  • Customer Service: Responsive communication and support for inquiries and technical questions.
  • Supply Chain Reliability: A stable track record and capacity to meet ongoing demand.

For companies looking to optimize their procurement strategy, identifying multiple potential manufacturers can provide leverage and ensure business continuity. It is advisable to request quotes from several suppliers, comparing not only the price but also the overall value proposition, including lead times and support services.

The market for pharmaceutical intermediates is competitive, and diligent supplier selection is key. By focusing on these criteria, R&D scientists and procurement managers can confidently source 6,7-Dimethoxy-3,4-dihydroquinazolin-4-one, ensuring their projects are supported by high-quality materials and dependable partnerships.